市場消息：歐盟國家將烏克蘭難民的保護延長至2028年3月。

China’s National Healthcare Security Administration, ahead of the planned release of the disease-based payment (DRG/DIP) 3.0 grouping scheme, convened another consultation to solicit feedback. Participants included the National Health Commission Hospital Management Research Institute, the DRG/DIP technical guidance group, representatives from seven major hospitals (including Peking Union Medical College Hospital, Peking University People’s Hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine and West China Hospital of Sichuan University), clinical staff, insurance experts and media representatives to refine pre-release communication and implementation details.

A-shares closed lower after intra-day rallies: Shanghai Composite -0.29%, Shenzhen Composite -0.97%, ChiNext -1.21%. Combined turnover on the Shanghai-Shenzhen bourses was about 2.571 tln yuan, down ~132.815 bln yuan versus the prior session. Medical services outperformed, with RuiZhi Pharma, Zhaoyan New Drug and Baihua Pharma hitting limit-up; Wanbang Pharma, Nanmo Biotech and Sunshine Nuohuo led gains. Baijiu stocks recovered from an early dip; Gujinggong, Jinzongzi and others hit limit-up, while Luzhou Laojiao, Shanxi Fenjiu, Jinshiyuan and Yingjia Gongjiu posted notable gains. Semiconductor and PCB-related compute-hardware names opened higher then slid: Qingyi Optoelectronics, Zhenbao Tech, Qiangyi Tech, Moxi and Dongwei Semiconductor fell more than 10%. Memory-chip names were weak—Baiwei Storage fell over 15%, while Demingli, Shenkeji and Lianwei Micro hit limit-down.